A recent study on the use of AstraGin, a proprietary ingredient derived from the roots of Astragalus membranaceus and Panax notoginseng, has shown that it promotes gut health in patients with ulcerative colitis. This study was published in the Journal of Biochemistry and Biotechnology.
The randomized, double-blind parallel study investigated the effect of AstraGin on the gut microbiota and immune response in eight ulcerative colitis patients aged 20-80. The participants were given either an AstraGin capsule or a placebo each day before breakfast and dinner for three months.
The study found that AstraGin supplementation led to a significant increase in beneficial gut bacteria, including a 420% increase in Faecalibacterium prausmitzii and a 180% increase in Bifidobacterium adolescentis. Additionally, AstraGin was found to decrease the growth of harmful bacteria. Furthermore, AstraGin was shown to enhance the body’s immune response, with an 11% increase in neutrophil cells and a 20.5% increase in lymphocyte immune cells. AstraGin also improved the absorption of L-arginine compared to the control group.
These findings suggest that AstraGin has a positive impact on various aspects of gut health. The researchers at NuLiv Science have explored multiple pathways through which AstraGin supports bioavailability, and the results indicate that AstraGin promotes a healthier intestinal environment. Based on the results of the study, it may be concluded that patients with ulcerative colitis may benefit from the use of AstraGin as a dietary supplement.
